MAHDAL, Michal, Tomáš TOMÁŠ, Vasileios APOSTOLOPOULOS, Dagmar ADÁMKOVÁ, Peter MÚDRY, Iva STANICZKOVÁ ZAMBO and Lukáš PAZOUREK. Proximal Tibia Tumour Location and Curettage Are Major Risk Factors of Local Recurrence in Giant Cell Tumour of Bone. Cancers. BASEL: MDPI, 2023, vol. 15, No 18, p. 1-10. ISSN 2072-6694. Available from: https://dx.doi.org/10.3390/cancers15184664.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Proximal Tibia Tumour Location and Curettage Are Major Risk Factors of Local Recurrence in Giant Cell Tumour of Bone
Authors MAHDAL, Michal (203 Czech Republic, guarantor, belonging to the institution), Tomáš TOMÁŠ (203 Czech Republic, belonging to the institution), Vasileios APOSTOLOPOULOS (203 Czech Republic, belonging to the institution), Dagmar ADÁMKOVÁ (203 Czech Republic, belonging to the institution), Peter MÚDRY (203 Czech Republic, belonging to the institution), Iva STANICZKOVÁ ZAMBO (203 Czech Republic, belonging to the institution) and Lukáš PAZOUREK (203 Czech Republic, belonging to the institution).
Edition Cancers, BASEL, MDPI, 2023, 2072-6694.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.200 in 2022
RIV identification code RIV/00216224:14110/23:00132519
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3390/cancers15184664
UT WoS 001079867600001
Keywords in English GCTB; denosumab; targeted treatment; bone; neoplasia
Tags 14110112, 14110123, 14110321, 14110811, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 14/2/2024 09:42.
Abstract
Giant cell tumour of bone (GCTB) is one of the most common local aggressive tumourous lesions with a wide variety of biological behaviour. However, there are no clear indicative criteria when choosing the type of procedure and the complication rates remain high, especially in terms of local recurrence. The purpose of the study was to (1) identify the main risk factors for local recurrence, (2) evaluate the recurrence-free survival in dependence on neoadjuvant denosumab use and the type of procedure, and (3) compare the functional outcomes after curettage and en bloc resection. The group included 102 patients with GCTB treated between 2006 and 2020. The mean age of patients was 34.4 years (15-79). The follow-up period was 8.32 years (2-16) on average. Local recurrence occurred in 14 patients (29.8%) who underwent curettage and in 5 patients (10.6%) after en bloc resection. Curettage was shown to be a factor in increasing recurrence rates (OR = 3.64 [95% CI: 1.19-11.15]; p = 0.023). Tibial location was an independent risk factor for local recurrence regardless of the type of surgery (OR = 3.22 [95% CI: 1.09-9.48]; p = 0.026). The recurrence-free survival rate of patients treated with resection and denosumab was higher compared to other treatments at five years postoperatively (p = 0.0307). Functional ability and pain as reported by patients at the latest follow-up were superior after curettage compared to resection for upper and lower extremity (mean difference: -4.00 [95% CI: -6.81 to -1.18]; p < 0.001 and mean difference: -5.36 [95% CI: -3.74 to -6.97]; p < 0.001, respectively). Proximal tibia tumour location and curettage were shown to be major risk factors for local recurrence in GCTB regardless of neoadjuvant denosumab treatment. The recurrence-free survival rate of patients treated with resection and denosumab was higher compared to other treatments. The functional outcome of patients after curettage was better compared to en bloc resection.
Links
MUNI/A/1395/2022, interní kód MUName: Personalizovaná léčba v dětské onkologii: multimodální theranostický přístup a „N-of-1 clinical trials“
Investor: Masaryk University
NU22-10-00054, research and development projectName: Nalezení nových terapeutických cílů pro léčbu obrovskobuněčného kostního nádoru
Investor: Ministry of Health of the CR, Subprogram 1 - standard
PrintDisplayed: 7/7/2024 01:06